CRISPR Therapeutics AG
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
CRSP | NDAQ
Overview
Corporate Details
- ISIN(s):
- CH0334081137
- LEI:
- Country:
- United States of America
- Address:
- BAARERSTRASSE 14, 0 ZUG
- Website:
- https://crisprtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CRISPR Therapeutics AG is a leading gene-editing company focused on developing transformative, gene-based medicines for serious diseases. As a pioneer of the revolutionary CRISPR/Cas9 technology, the company translates cutting-edge science into potential cures. Its diverse clinical pipeline targets a broad range of disease areas, including hemoglobinopathies, immuno-oncology, regenerative medicine, and cardiovascular disease. The company achieved a major milestone with the development and approval of CASGEVY™, the first-ever CRISPR-based therapy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CRISPR Therapeutics AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CRISPR Therapeutics AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CRISPR Therapeutics AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
